EPG Online Twitter 
EPG Online Blog 
Disease Knowledge Drug Updates
- Fostair 100/6 inhalation solution
- Epanutin capsules 25, 50 and 100mg
- Eprex 2000, 4000 and 10000 IU/ml solution for injection in pre-filled syringe
- FemSeven Conti
- Epanutin 300mg hard capsules
- Bedranol 80mg SR Capsules
- Bedranol 160mg SR Capsules
- Betim 10mg Tablets
- Carbo-Dome Cream
- Bisoprolol 2.5mg/5mg/10mg film coated tablet
- Phenergan Injection
- Rivotril 0.5 mg and 2 mgTablets
- Rivotril Ampoules
- RELPAX 20mg and 40mg Film-Coated Tablets
- Witch Doctor ® 81.5%w/w Gel
- Levetiracetam Actavis 1,000 mg film-coated tablets
- Levetiracetam Actavis 250 mg film-coated tablets
- Levetiracetam Actavis 500 mg film-coated tablets
- Levetiracetam Actavis 750 mg film-coated tablets
- Lidocaine Hydrochloride Injection BP 1% w/v plastic ampoules
- Lidocaine Hydrochloride Injection BP 2.0% w/v
- Omeprazole 10mg Capsules
- Omeprazole 20mg Capsules
- Panadol Extra Advance 500 mg/65 mg Tablets
- Allopurinol Tablets BP 300mg
- Allopurinol Tablets BP 100mg
- Anadin Ultra Double Strength 400mg Capsules/Anadin LiquiFast 400mg Capsules
- Calcipotriol Scalp Solution
- Bupivacaine Hydrochloride Injection BP 0.5% w/v.
- Lescol (fluvastatin* sodium) 20 mg and 40 mg capsules
- Meropenem 1 g Powder for Solution for Injection or Infusion
- VALTREX Tablets 250mg
- Vesicare 5mg & 10mg film-coated tablets
- Zomig 5mg Nasal Spray
- Water for Injections
- Tizanidine 2mg Tablets
- NovoRapid 100 U/ml in a vial, NovoRapid Penfill 100 U/ml, NovoRapid FlexPen 100 U/ml, NovoRapid FlexTouch 100 U/ml
- Orfadin 10 mg hard capsules
- Orfadin 2 mg hard capsules
- Natecal D3 Chewable Tablets
Non-Small Cell Lung Cancer (NSCLC)
Please note- The EPG Non-Small Cell Lung Cancer (NSCLC) Knowledge Centre is for Doctors and other Healthcare Professionals. Enter the Non-Small Cell Lung Cancer (NSCLC) Knowledge Centre.
The NSCLCs account for 80% of all lung cancers and can be further subdivided into squamous-cell carcinoma, large-cell carcinoma and adenocarcinoma (which includes bronchioloalveolar-cell carcinoma [BAC]).
At the start of the millennium, it was estimated that there were 10 million new cancer cases worldwide per annum
The causes of lung cancer are thought to be almost exclusively environmental, although susceptibility is modulated by protective elements such as genetic factors and diet.1
The staging of lung cancer is based on the size and invasiveness of the primary tumour (T), absence, presence and degree of regional lymph node (N) involvement, and the metastatic spread to distant organs and lymph nodes (M), or TNM system.
In around 5% of cases, usually of early-stage disease, initial presentation is a chance finding during routine examination for other conditions and no symptoms are evident.
Following presentation and diagnosis of NSCLC, thorough examination allows determination of the disease stage to provide a prognosis at the individual patient level.
The treatment strategies for NSCLC are principally dictated by clinical stage with modulation according to patient preferences and characteristics such as age and PS
The four primary treatment modalities used in the management of patients with NSCLC are:2
- Surgery
- Radiation therapy
- Combination chemotherapy
- Targeted therapy
Enter the Non-Small Cell Lung Cancer (NSCLC) Knowledge Centre
What’s in the Non-Small Cell Lung Cancer (NSCLC) Knowledge Centre?
- Home
- Non-small Cell Lung Cancer
- Causes
- Risk Factors
- Histology/Pathology
- Disease Staging/Prognosis
- TNM Systems
- Factors that affect prognosis
- Signs and Symptoms
- Diagnosis
- Early Stage disease (stage I, II, IIIA)
- Treatment Strategies
- Advanced disease (stage IV)
- Quality of Life in advanced NSCLC
- Future Strategies
- Treatment Therapies
- Chemotherapy
- First-line Therapy
- Second-line Therapy
- Unmet clinical need in advanced NSCLC
- Targeted therapies - Overview of cytotoxic drugs
- Recent developments in Cancer Cell Biology
- Current therapy - Erlotinib
- Resources
- Downloads - Physicians Materials
- Patient
- Downloads - Patient support
References:
1. Alberg AJ, Samet JM. Epidemiology of lung cancer. Chest 2003;123:21S–49S.
2. Putnam JB, Fossella FV, Komaki R, eds. Implementation of multidisciplinary care in the treatment of patients with lung cancer. In: Fossella FV, Komaki R, Putnam JB, eds. Lung Cancer. New York, NY: Springer-Verlag; 2003:1-24
- Gemcitabine 200mg Powder for Solution for Infusion
... contraindicated. Non-Small Cell Lung Cancer : Locally advanced or metastatic non-small cell lung cancer in combination with other cytostatic medicinal products. Palliative treatment of adult patients with locally advanced or metastatic non-small cell lung cancer . Pancreatic Cancer: Locally advanced ... - Tarceva 25mg, 100mg and 150mg Film-Coated Tablets
Non-small cell lung cancer (NSCLC) : Tarceva is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR activating mutations. Tarceva is also indicated as monotherapy for maintenance treatment in patients with locally ... - Taxceus 20mg/ml concentrate for solution for infusion
... chemotherapy. Previous therapy should have included an anthracycline. Non-small cell lung cancer Taxceus is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior chemotherapy. Taxceus in combination with cisplatin is ... - Docefrez 20 mg powder and solvent for concentrate for solution for infusion
... chemotherapy. Previous therapy should have included an anthracycline. Non-small cell lung cancer Docetaxel is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior chemotherapy. Docetaxel in combination with cisplatin is ... - Gemzar 200mg powder for solution for infusion, Gemzar 1000mg powder for solution for infusion
... Gemcitabine, in combination with cisplatin, is indicated as first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). Gemcitabine monotherapy can be considered in elderly patients or those with performance status 2. Gemcitabine is indicated for the ... - Iressa 250mg film-coated tablets
IRESSA is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating mutations of EGFR-TK ...
